These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2340201)

  • 1. A sensitive radioimmunoprecipitation assay for the detection and quantitation of antibodies to the envelope glycoprotein gp120 of the human immunodeficiency virus (HIV-1).
    Lucas C; Peterson ML; Bennett GL; Frie SW; Berman PW; Chen AB
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):357-70. PubMed ID: 2340201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1.
    Anderson KP; Lucas C; Hanson CV; Londe HF; Izu A; Gregory T; Ammann A; Berman PW; Eichberg JW
    J Infect Dis; 1989 Dec; 160(6):960-9. PubMed ID: 2555423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.
    Krohn K; Robey WG; Putney S; Arthur L; Nara P; Fischinger P; Gallo RC; Wong-Staal F; Ranki A
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4994-8. PubMed ID: 2440037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.
    Berman PW; Groopman JE; Gregory T; Clapham PR; Weiss RA; Ferriani R; Riddle L; Shimasaki C; Lucas C; Lasky LA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5200-4. PubMed ID: 2455898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the serological cross-reactivity between glycoproteins of the human immunodeficiency virus and equine infectious anaemia virus.
    Montelaro RC; Robey WG; West MD; Issel CJ; Fischinger PJ
    J Gen Virol; 1988 Jul; 69 ( Pt 7)():1711-7. PubMed ID: 2839603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine.
    Stephens DM; Eichberg JW; Haigwood NL; Steimer KS; Davis D; Lachmann PJ
    J Gen Virol; 1992 May; 73 ( Pt 5)():1099-106. PubMed ID: 1375277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.
    Morrow WJ; Williams WM; Whalley AS; Ryskamp T; Newman R; Kang CY; Chamat S; Köhler H; Kieber-Emmons T
    Immunology; 1992 Apr; 75(4):557-64. PubMed ID: 1592430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
    Dickey C; Ziegner U; Agadjanyan MG; Srikantan V; Refaeli Y; Prabhu A; Sato A; Williams WV; Weiner DB; Ugen KE
    DNA Cell Biol; 2000 Apr; 19(4):243-52. PubMed ID: 10798448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
    Devash Y; Rusche JR; Nara PL
    Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmation of HIV seropositivity: comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture.
    Tersmette M; Lelie PN; van der Poel CL; Wester MR; de Goede RE; Lange JM; Miedema F; Huisman JG
    J Med Virol; 1988 Jan; 24(1):109-16. PubMed ID: 2828529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and function of HIV-1 CRF01_AE envelope proteins from blood and genital fluid isolates.
    Horthongkham N; Athipanyasilp N; Siritantikorn S; Kantakamalakul W; Srisurapanon S; Sutthent R
    Southeast Asian J Trop Med Public Health; 2009 May; 40(3):480-93. PubMed ID: 19842433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.
    Cleland JL; Lim A; Daugherty A; Barron L; Desjardin N; Duenas ET; Eastman DJ; Vennari JC; Wrin T; Berman P; Murthy KK; Powell MF
    J Pharm Sci; 1998 Dec; 87(12):1489-95. PubMed ID: 10189254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies.
    Toriyoshi H; Shioda T; Sato H; Sakaguchi M; Eda Y; Tokiyoshi S; Kato K; Nohtomi K; Kusagawa S; Taniguchi K; Shiino T; Kato A; Foongladda S; Linkanonsakul S; Oka SI; Iwamoto A; Wasi C; Nagai Y; Takebe Y
    AIDS Res Hum Retroviruses; 1999 Aug; 15(12):1109-20. PubMed ID: 10461831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.